Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute of Sept 199/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/817,549			
Filing Date	April 2, 2004			
First Named Inventor	Ron Waksman et al.			
Art Unit	3763			
Examiner Name				
Attorney Docket Number	0341-0030.42			

Sheet 18 of 149 **U. S. PATENT DOCUMENTS** Examiner Cite **Document Number** Publication Date Name of Patentee or Pages, Columns, Lines, Where MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Initials* Number-Kind Code^{2 (f known)} Figures Appear US- 5,503,614 04-02-1996 Liprie MF) ^{US-} 5,533,969 07-09-1996 Mulder US-5,556,389 09-17-1996 Liprie US-5,575,749 11-19-1996 Liprie US-5,624,372 04-29-1997 Liprie 07-01-1997 ^{US-} 5,643,171 Bradshaw, et al. US-5,713,828 02-03-1998 Coniglione US-5,807,231 09-15-1998 Liprie US-5,840,064 11-24-1998 Liprie US-5.851,172 12-22-1998 Bueche, et al. ^{US-} 5,857,956 01-12-1999 Liprie US- 5.863,284 01-26-1999 Klein ^{US-} 5,899,882 05-04-1999 |Waksman, et al. US- 6,013,020 01-11-2000 Meloul, et al. us-6,074,338 06-13-2000 Popowski, et al. us- 6,306,074 Waksman, et al. 10-23-2001 US-6,458,070 Waksman, et al. 10-01-2002 ^{US-} 6.503,185 01-07-2003 Waksman, et al. ^{US-} 6,514,193 02-04-2003 Kaplan

	FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
	Country Code ³ "Number ⁴ "Kind Code ⁵ (# known)	MM-DD-YYYY		Or Relevant Figures Appear	T
					L
				·	L
					L
-					L
					Г

Examiner Signature	Mattlal	Dat Cou	nte ensidered	12/12/09

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Wind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need essistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/817,549 Filing Date April 2, 2004 INFORMATION DISCLOSURE First Named Inventor Ron Waksman et al. STATEMENT BY APPLICANT Art Unit 3763 (Use as many sheets as necessary) **Examiner Name**

Attorney Docket Number | 0341-0030.42 Sheet 72

Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MFD		^{US-} 2,750,517	06-12-1956	Baum	
7		^{US-} 2,965,761	12-20-1960	Horvath .	
		us- 3,088,032	04-30-1963	Brunton	
		^{US-} 4,471,765	09-18-1984	Strauss, et al.	
•		^{US-} 4,883,459	11-28-1989	Calderon	
		^{US-} 5,472,403	12-05-1995	Comacchia, et al.	
		^{US-} 5,554,119	09-10-1996	Harrison, et al.	
		US- 5,618,226	04-08-1997	Liprie	
		^{US-} 5,683,345	11-04-1997	Waksman, et al.	
1		US- 6,071,227	06-06-2000	Popowski, et al.	
· V		US-			
	<u> </u>	US-			
		US-			

	FORE	GN PATENT DOCU	FOREIGN PATENT DOCUMENTS								
Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	7-8						
	Country Code ³ Number ⁴ Kind Code ⁵ (# known)	MM-DD-YYYY		Or Relevant Figures Appear							
		1									
		· ·									
					П						

Date Examiner Considered Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. The reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	Substitute for form 1449/PTO		Complete if Known		
Jubsilu				Application Number	10/817,549
INF	ORMATION	N DIS	SCLOSURE	Filing Date	April 2, 2004
STA	STATEMENT BY APPLICANT			First Named Inventor	Ron Waksman et al.
	##			Art Unit	3763
	(Use as many sheets as necessary)			Examiner Name	
Sheet	8 3	of	149	Attorney Docket Number	0341-0030.42

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MFD 1		NISAR SYED A.M., FEDER B., "Technique of After-Loading Interstitial Implants", Syed/Feder, Radiologia Clinica 46:458-476 (1977).	
2		NISAR SYED et al., "Combination of External and Interstitial Irradiation in the Primary Management of Breast Carcinoma", CANCER vol. 46, No. 6, pp. 1360-1365 (1980).	
	PUTHAWALA et al., "Temporary Iridium 192 Implant in the Management of Carcinoma of the Prostate", ENDOCURIETHERAPY/HYPERTHERMIA ONCOLOGY 1:25-34 (1985).		
	NISAR SYED et al., "Transperineal Interstitial-Intracavitary "Syed-Neblett" Applicator in the Treatment of Carcinoma of the Uterine Cervix", ENDOCURIETHERAPY/HYPERTHERMIA ONC-		
OLOGY 2:1-13 (1985).		OLOGY 2:1-13 (1985).	_
	5	NISAR SYED A.M. et al., "Intraluminal Irradiation in the Treatment of Esophogeal Cancer", ENDOCURIETHERAPY/HYPERTHERMIA ONCOLOGY 3:105-113 (1987).	
	6	FAXON et al., "Mechanism of Angioplasty and Its Relation to Restenosis", AMERICAN JOURNAL OF CARDIOLOGY 15:5B-9B (1987).	
	7	BOROK et al. "Rule of Ionizing Irradiation for 393 Keloids", I.J. RADIATION ONCOLOGY-BIOLOGY-PHYSICS 17:77-80 (1989).	
	8	KOVALIC/PEREZ, "Radiation Therapy Following Keloidectomy: A 20-Year Experience", I.J. RADIATION ONCOLOGY-BIOLOGY-PHYSICS 17:77-80 (1989).	
	9	MCCORMICK et al., "Breast Cancer", Chpt. 25 of INTERSTITIAL BRACHYTHERAPY 221-226 (1990).	

Examiner	A LAV	Date	17 / /
Signature	/ Martinal	Considered	12/12/04

^{*}EXAMINER: tritial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. OO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Subetitu	Substitute for form 1449/PTO			Complete if Known		
30030111	101011011111111111111			Application Number	10/817,549	
INF	ORMATION	DIS	CLOSURE	Filing Date	April 2, 2004	
STA	TEMENT B	BY A	PPLICANT	First Named Inventor	Ron Waksman et al.	
	Atra as many about	-4		Art Unit	3763	
	(Use as many sheets as necessary)			Examiner Name	·	
Sheet	84	of	149	Attorney Docket Number	0341-0030.42	

		NON PATENT LITERATURE DOCUMENTS	•	
Examiner Initials*	r Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), titl the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-is number(s), publisher, city and/or country where published.			
mfo 1		DAWSON, "Theoretic Considerations Regarding Low-Dose Radiation Therapy for Prevention of Restenosis after Angioplasty", THE READING HOSPITAL & MEDICAL CENTER 18(1) 4-7 (1991).	_	
1	11	Skin, p. 261 of the American Medical Association Family Medical Guide, Editor Kunz.		
	12	Endovascular Low-Dose Irradiation Inhibits Neointima Formation after Coronary Artery Balloon Injury in Swine - A Possible Role for Radiation Therapy in Restenosis Prevention,		
		by Ron WAKSMAN, MD; Keith A. ROBINSON, PhD; Ian R. CROCKER, MD; Michael B. GRAVANIS, MD; Gustavo D. CIPOLLA, DVM; Spencer B. KING III, MD, CIRCULATION vol. 91, No. 5, pp. 1533		
		-1539 (Mar. 1, 1995). Submitted for publication Oct. 3, 1994.		
	13	Endovascular Low-Dose Irradiation Inhibits Neointima Formation after Coronary Artery Balloon Injury in Swine - A Possible Role for Radiation Therapy in Restenosis Prevention,		
		by Ron WAKSMAN, MD; Keith A. ROBINSON, PhD; Ian R. CROCKER, MD; Gustavo D. CIPOLLA, DVM; Spencer B. KING III, MD. Submitted for publication Mar. 25, 1994.		
	14	SCHWARTZ et al., "Effect of External Beam Irradiation on Neointimal Hyperplasia after Experimental Coronary Artery Injury", American College of Cardiology, JACC vol. 19,		
		No. 5, (Apr. 1992), pp. 1106-1113.		
	15	STEIDLE, B., "Preventative Percutaneous Radiation Therapy to Avoid Hyperplasia of the Intima after Angioplasy Combined with Stent Implantation", STRAHLENTHER ONKOL, (1994),		

Examiner	1	Date	
Signature	/ United	Considered	12/12/04

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicants.

1 Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2005. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
3 8 collection of information unless it contains a well-d OMB control with the control of the contr

	te for form 1449/PTO		•	Complete If Known		
Subsutu	ne tortomi 1449/PTO			Application Number	10/817,549	
INF	ORMATION	N DIS	CLOSURE	Filing Date	April 2, 2004	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Ron Waksman et al.	
	(Use as many sheets as necessary)			Art Unit	3763	
				Examiner Name		
Sheet	1875	of	149	Attorney Docket Number	0341-0030.42	

		NON PATENT LITERATURE DOCUMENTS					
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
M PD		170:151-154.	_				
	16	WIEDERMANN et al., "Effects of High-Dose Intracoronary Irradiation on Vasomotor Function and Smooth Muscle Histopathology", AMERICAN PHYSIOLOGICAL SOCIETY, (1994), pp. H125-					
		H132.					
	17	ABBAS et al., "External Beam Irradiation Inhibits Neointimal Hyperplasia Following Balloon Angioplasty", INTERNATIONAL JOURNAL OF CARDIOLOGY, 44 (1994), 191-202.					
	18	LIERMANN et al., "Interventional Treatment and Clinics in Combination with Prophylactic Endovascular Radiation in the Therapy of Intimal Hyperplasia", RADIOLOGE, (1994) 34,					
		524-533.					
	19	SHIMOTAKAHAR and MAYBERG, "Gamma Irradiation Inhibits Neointimal Hyperplasia in Rats after Arterial Injury", STROKE, vol. 25, No. 2, pp. 424-428, (Feb. 1994).					
	20	WIEDERMANN et al., "Intracoronary Irradiation Markedly Reduces Restenosis after Balloon Angioplasty in a Porcine Model", American College of Cardiology, JACC, vol. 23, No. 6,					
		pp. 1491-1498 (May 1994).					
	21	FISCHELL et al., "Low-Dose, Beta-Particle Emission from 'Stent' Wire Results in Complete, Localized Inhibition of Smooth Muscle Cell Proliferation", BASIC SCIENCE REPORTS,					

Examiner Signature	Matgal	Date Considered	12/12/04
0.5	2 420 / 20		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Cubathu	e for form 1449/PTO			Complete if Known		
Subsului	91011011111149710			Application Number	10/817,549	
INFO	DRMATION	I DIS	CLOSURE	Filing Date	April 2, 2004	
(Use as many sheets as necessary)				First Named Inventor	Ron Waksman et al.	
				Art Unit	3763	
				Examiner Name		
Sheet	46	of	149	Attorney Docket Number	0341-0030.42	

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	T ²
Initials* No.1		the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
MFD		Circulation, vol. 90, No. 6, (Dec. 1994), pp. 2956-2963.	
1	22	FRIEDMAN, "Pathogenesis of the Spontaneous Atherosclerotic Plaque", ARCHIVES OF PATHOLOGY, vol. 76, (Sept. 1963), 94-105.	
	23	FRIEDMAN et al., "Cortisone and Experimental Atherosclerosis", ARCHIVES OF PATHOLOGY, vol. 77, (Feb. 1964), 56-72.	
	FRIEDMAN et al., "Aortic Atherosclerosis Intensification in Rabbits by Prior Endothelial Denudation", ARCHIVES OF PATHOLOGY, vol. 79, (Apr. 1965), 345-356.		
	FRIEDMAN and BYERS, "Effect of Iridium 192 Radiation on Thromboatherosclerotic Plaque in the Rabbit Aorta", ARCHIVES OF PATHOLOGY, vol. 80, (Sep. 1965).		
	26	FRIEDMAN, FELTON, and BYERS, "The Antiatherogenic Effect of Indium 192 upon the Cholesterol-fed Rabbit", Journal OF CLINICAL INVESTIGATION, vol. 43, No. 2, (1964), 185-192.	
	27	HILARIS, B.S., et al., ATLAS OF BRACHYTHERAPY Chapter 2, "Brachytherapy Instruments", title & cover pages, p. 28, pp. 42-43, (1988).	
	MELKERT, R., et al., "Luminal Narrowing after Percutaneous Transluminal Coronary Angioplasty. A Multivariate Analysis of Clinical, Procedural and Lesion Related Factors		
		Affecting Long-term Angiographic Outcome in the PARK Study", J. INVASIVE CARDIOLOGY, vol. 6, No. 5, pp. 160-171 (Jun. 1994).	
	29	FISHMAN, D., et al., Abstract: "A Randomized Comparison of Coronary-stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease", NEW ENGLAND J. OF	

Examiner	Matter 11	Date	12/12/04
Signature	raw res	Considered	12112109

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's include copy of this form with next communication to applicant.

1 Applicant's include citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SE/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/F		ct or 1995, no persons a	Complete if Known		
Substitute for form 1443/P	10		Application Number	10/817,549	
INFORMATION	ON DIS	CLOSURE	Filing Date	April 2, 2004	
STATEMENT BY APPLICANT			First Named Inventor	Ron Waksman et al.	
			Art Unit	3763	
(Use as many sheets as necessary)			Examiner Name		
Sheet 12 7	of	1×9	Attorney Docket Number	0341-0030.42	

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MFD		MEDICINE, p. 496 (Aug. 25, 1994).	
	30	NICOLINI, F., et al., "Biology of Restenosis and Therapeutic Approach", ENDOVASCULAR SURGERY, vol. 72, No. 4, pp. 919-935 (Aug. 1992).	
	31	WEIDERMANN, J., et al., Abstract: "Intracoronary Irradiation Acutely Impairs Endothelial and Smooth Muscle Function as Assessed by Intravascular Ultrasound", Supplement to	
		CIRCULATION, vol. 86, No. 4, p. I-188, Abstract No. 0750 (Oct. 1992).	
	32	LANDAU, C., et al., "Percutaneous Transluminal Coronary Angioplasty", NEW ENGLAND J. OF MED., vol. 3330, No. 14, pp. 981-983 (Apr. 7, 1994).	
	33	PARANANDI, S., et al., "Contemporary Clinical Trials of Restenosis", J. OF INVASIVE CARDIOLOGY, vol. 6, No. 4, pp. 109-123 (May 1994).	
	34	WIEDERMANN et al., "Intracoronary Irradiation Markedly Reduces Restenosis after Balloon Angioplasty in a Porcine Model", JACC, vol. 23, No. 6, pp. 1491-1498 (May 1994).	
	35	GLAGOV, S., "Intimal Hyperplasia, Vascular Modeling, and the Restenosis Problem", CIRCULATION, vol. 89, No. 6, pp. 2888-2891 (Jun. 1994).	_
	36	BOTTCHER et al., "Endovascular Irradiation - A New Method to Avoid Recurrent Stenosis after Stent Implantation in Peripheral Arteries: Technique and Preliminary Results", I.J.	
		RADIATION ONCOLOGY, BIOLOGY, PHYSICS, vol. 29, (Nov. 1994), 183-186.	

Examiner	11.41/1	Date	12/2/11
Signature	Mullim	Considered	12/12/04

*EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form ant/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
D a collection of information unless it contains a unit of the collection of information unless it contains a unit of the collection of information unless it contains a unit of the collection of information unless it contains a unit of the collection of information unless it contains a unit of the collection of information unless it contains a unit of the collection of information unless it contains a unit of the collection of the coll

	er the Paperwork Red				Complete if Known		
Substitute for form 1449/PTO					Application Number	10/817,549	
INFO	RMATION	DIS	CLC	DSURE	Filing Date	April 2, 2004	
STA	STATEMENT BY APPLICANT			ICANT	First Named Inventor	Ron Waksman et al.	
					Art Unit	3763	
(Use as many sheets as necessary)					Examiner Name		
Sheet	188	of	14	9	Attorney Docket Number	0341-0030.42	

		NON PATENT LITERATURE DOCUMENTS				
Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
MPD	37	LIERMANN et al. "Prophylactic Endovascular Radiotherapy to Prevent Intimal Hyperplasia after Stent Implantation in Femoropopliteal Arteries", CARDIOVASCULAR AND INTERVENTIONAL				
		RADIOLOGY, (1994), 17:12-16.				
	38	Supplementary European Search Report - EP 97 92 2288.				
Annex to the European Search Report on European Patent Appli No. EP 97 92 2288.		Annex to the European Search Report on European Patent Application No. EP 97 92 2288.				
HERRMAN, J., et al., "Pharmacological Approaches to the Prevention of Restenosis Following Angioplasty", DRUGS, 46(1): pp. 18-52 (1993).		HERRMAN, J., et al., "Pharmacological Approaches to the Prevention of Restenosis Following Angioplasty", DRUGS, 46(1): pp. 18-52 (1993).				
	41	LANGE, R., et al., "Southwestern Internal Medicine Conference: Restenosis: The Achilles Heel of Coronary Angioplasty", AMER. J. OF THE MEDICAL SCIENCES, vol. 306, pp. 265-273				
		(Oct. 1993)				
	42	MYLER, R., et al., "Restenosis after Coronary Angioplasty: Pathophysi- ology and Therapeutic Implications (Part 1 of Two Parts), J. OF INVASIVE CARDIOLOGY, vol. 5, No. 8,				
		pp. 278-285, (Oct. 1993).				
	43	WEIDERMANN, J., et al., Abstract: "Intracoronary Irradiation Markedly Reduces Restenosis after Balloon Angioplasty in a Porcine Model", Supplement of CIRCULATION, vol. 88,				

Examiner	Mr. W.	Date	12/12/20
Signature	THE	Considered	12/12/04

^{*}EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Onsidered, include copy or trus form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a serial CALP and the collection of information unless it contains a serial CALP and the collection of information unless it contains a serial CALP and the collection of information unless it contains a serial CALP and the collection of information unless it contains a serial CALP and the collection of information unless it contains a serial CALP and the collection of information unless it contains a serial CALP and the collection of information unless it contains a serial CALP and the collection of information unless it contains a serial call and the collection of information unless it contains a serial call and the collection of information unless it contains a serial call and the collection of information unless it contains a serial call and the collection of information unless it contains a serial call and the collection of information unless it contains a serial call and the collection of information unless it contains a serial call and the collection of information unless it contains a serial call and the collection of information unless it contains a serial call and the collection of the

Under the Paperwork Reduction Act of 1995, no persons an Substitute for form 1449/PTO	Complete if Known		
Substitute for form 1444/PTO	Application Number	10/817,549	
INFORMATION DISCLOSURE	Filing Date	April 2, 2004	
STATEMENT BY APPLICANT	First Named Inventor	Ron Waksman et al.	
	Art Unit	3763	
(Use as many sheets as necessary)	Examiner Name		
Sheet 14 9 of 14 9	Attorney Docket Number	0341-0030.42	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
MPD		No. 4, pt. 2, p. I-655, Abstract No. 3529 (Oct. 1993).	
1	44	Office Action for Serial Number 10/411,749 dated March 29, 2004.	
•			
· · · · · · · · · · · · · · · · · · ·			

Examiner Signature	Marghe	1 -	Date Considered	12/12/or

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy or this form with next communication to applicam.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



			Atty. Docket No. 0341-0030.42		<u>Serial No.</u> Not Assigned						
•	r of publicatio		Applicant Ron WAKSMAN et al								
			<u>Filing Date</u> Herewith	Group	·						
U.S. PATENT DOCUMENTS											
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE					
j:VFO	4,733,653 4,955,895 5,084,001 5,267,954 5,334,154 5,413,557 5,501,227 5,540,236 5,540,659 5,545,137 5,624,392 5,843,028	03/29/88 09/11/90 01/28/92 12/07/93 08/02/94 05/09/95 03/26/96 07/30/96 07/30/96 08/13/96 04/29/97 12/01/98	Leung et al Sugiyama et al van't Hooft et al Nita Samson et al Solar Yock Ginn Teirstein Rudie et al Saab Weaver et al	128 606 600 604 604 128 128 604 604 604	1.2 194 3 22 102 96 662.06 772 104 96 43 54	11/25/85 06/22/89 08/09/90 05/05/92 08/04/92 08/24/93 09/17/93 08/05/94 08/30/94 03/30/95 08/08/94					
		FOREI	GN PATENT DOCUMENTS	S							
	DOCUMENT NUMBER	DATE	APPLICANT	English Abstract	English Trans.	FILING DATE					
WED	DE 1 095 963	12/29/60	Wachsmann		Х	07/15/59					
OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS (Including Author, Title, Date, Pertinent Pages)											
EXAMINER: MULLIANT DATE CONSIDERED: 12/12/04											
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP form. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.											